Prostate Cancer Risk Not Elevated with Testosterone Replacement
SAN DIEGO—Testosterone replacement therapy (TRT) does not increase the risk of prostate cancer (PCa) or overall cancer risk, according to a study presented at the American Urological Association 2013 annual meeting. In fact, researchers found that men on TRT had a lower incidence of PCa than those not on TRT.
Michael Eisenberg, MD, of the Stanford University School of Medicine in Palo Alto, Calif., and colleagues analyzed data from 750 patients. They linked these patients' records to the Texas Cancer Registry Database to determine the incidence of cancer. Of these 750 men, 333 men were on TRT and 417 were not. The study population had a mean of 8.7 years of follow-up.
Compared with the general population in Texas, men on TRT had an age-adjusted PCa standardized incidence rate (SIR) of 2.6, whereas men not on TRT had a PCa SIR of 3.7.
Compared with the general population, men on TRT had an age-adjusted SIR for any cancer of 1.5 where those not on TRT had an SIR of 1.7. After adjusting for age and year of evaluation, the researchers found no difference in the risk of any cancer between men on TRT and those not on TRT.